Chris Linthwaite has been Chief Executive Officer of Fluidigm since October 2016. Linthwaite has significant leadership experience across a broad range of life science businesses, including genomics tools, bioprocessing, forensics, agbio, and animal health testing. Prior to joining Fluidigm, Linthwaite served as President of the Genetic Sciences Division at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. Linthwaite has extensive experience building successful franchises in both life science research markets and a range of regulated environments. He has spearheaded numerous acquisitions and transformed business performance to drive growth.
Earlier in his career, he was in management consulting at two firms that are now part of PwC, and he co-founded a biomedical organization focused on early-stage technology commercialization. He served on the board of directors of pediatric genetic testing company Claritas Genomics.
As an armor officer in the American military, Linthwaite was stationed in Europe and served with distinction as part of the NATO-led Implementation Force conducting peacekeeping operations in Bosnia and Herzegovina.
He earned an MBA from the Darden School of Business at the University of Virginia as well as a BA in foreign affairs from UVA. Linthwaite served as a White House intern in the Office of Public Liaison and competed at the varsity level with the UVA wrestling team.
Vikram Jog has served as Chief Financial Officer since February 2008. From April 2005 to February 2008, he was Chief Financial Officer for XDx, Inc., a molecular diagnostics company. From March 2003 to April 2005, he was a Vice President of Applera Corporation and Vice President of Finance for its related businesses, Celera Genomics and Celera Diagnostics. From April 2001 to March 2003, he was Vice President of Finance for Celera Diagnostics and Corporate Controller of Applera Corporation. Jog holds a bachelor of commerce degree from Delhi University and an MBA from Temple University. He is a member of the American Institute of Certified Public Accountants.
Nick Khadder joined Fluidigm in June 2016 as Senior Vice President, General Counsel and Corporate Secretary. Prior to that he served as Senior Vice President, General Counsel and Corporate Secretary at Amyris, Inc., a Bay Area biotechnology company. Before joining Amyris, he served in senior counsel roles at LeapFrog Enterprises, Inc. and Protiviti Inc. from 2005 to 2010, and as a corporate attorney at Fenwick & West LLP from 1998 to 2005. Khadder received a BA from UC Berkeley and a JD from the UC Berkeley School of Law.
Colin McCracken has been Chief Commercial Officer of Fluidigm since March 2019. Prior to joining Fluidigm, McCracken was Vice President, Chromatography and Mass Spectrometry, EMEA, at Thermo Fisher Scientific. McCracken began his career in the medical devices space, later transitioning to a key account post with Bristol-Myers Squibb. Subsequently, he led major commercial operations in Europe for Invitrogen, Life Technologies and Thermo Fisher Scientific. McCracken is an honors graduate of the electrical and electronic engineering program at the University of Strathclyde in Glasgow.
Brad Kreger has served as Senior Vice President, Global Operations, since April, 2018. Prior to joining Fluidigm, Kreger held a senior leadership role in Manufacturing Operations, Clinical Next-Generation Sequencing for Thermo Fisher Scientific. Previously, he spent two decades at Affymetrix, where he served as VP, Reagent Manufacturing & Global Process Engineering. Kreger holds an MBA and M.Sc. from Western Governors University and a BS degree in biotechnology and business from Charter Oak State College.
Angela Peters is Chief Human Resources Officer for Fluidigm, having joined the company in July 2017. Peters has significant life sciences industry leadership experience in talent, organizational and cultural development. Prior to joining Fluidigm, she held senior human resources roles at such companies as Medivation, Thermo Fisher Scientific, and Life Technologies. She holds a BS in marketing and management from Notre Dame de Namur University.
Emi Zychlinsky, PhD, joined Fluidigm in April 2016 as Senior Vice President, Regulatory Affairs and Quality Assurance. From 2011 to April 2016, she was Chief Technical Officer for Diadexus, a diagnostics biotechnology company. She held a series of senior leadership positions at Hitachi Chemical Diagnostics, including Vice President of Operations and Vice President of Research and Development and Regulatory Affairs, from 1999 to 2011. Previously, Zychlinsky served in new product, R&D and technical development roles at NAXCOR and Mast Immunosystems. She holds a PhD in Medical Microbiology from Stanford University and a BA in Chemistry, Bacteriology and Parasitology from Escuela Nacional de Ciencia Biologicas in Mexico City.